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Abstract
Aim
Serum high mobility group box 1 protein (HMGB1) is a proinflammatory molecule that could
potentially serve as a biomarker for non-alcoholic fatty liver disease (NAFLD) and non-alco-
holic steatohepatitis (NASH) due to its correlation with degree of liver fibrosis. The aim of the
current study was to examine the cross-sectional and longitudinal relationships between
serum HMGB1 levels and liver histology in adults and children with NAFLD participating in
two large randomized controlled trials.
Methods
Serum HMGB1 levels were measured at various time points in adults and children with
NAFLD, who participated in PIVENS and TONIC clinical trials respectively. PIVENS trial
compared vitamin E or pioglitazone to placebo in adults whereas TONIC trial compared vita-
min E or metformin to placebo in children. Participants had liver biopsies at baseline and the
end of treatment (96 weeks), and liver histology was reviewed by a central committee of
study pathologists.
Results
In the cross-sectional analyses (n = 205 for PIVENS and 109 for TONIC), there was no sig-
nificant relationship between serum HMGB1 levels and histological features such as steato-
sis, ballooning, inflammation, fibrosis, or presence of steatohepatitis in either adults or
children. Serum HMGB1 levels did not change significantly during treatment either with pla-
cebo, vitamin E therapy (P = 0.81) or pioglitazone (P = 0.09) in the PIVENS trial. Similarly,
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serum HMGB1 levels did not change significantly during treatment either with placebo, met-
formin (P = 0.15) or vitamin E (P = 0.23) in the TONIC trial. In the longitudinal analyses (n =
105 for PIVENS and 109 for TONIC), changes in serum HMGB1 levels did not correlate with
histologic improvement or resolution of NASH in either adults or children. There was no rela-
tionship between serum HMGB1 and ALT levels in either adults or children with NAFLD.
Conclusion
Serum HMGB1 levels were not associated with histological severity or treatment response
in either children or adults with NAFLD.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is a common liver condition and is estimated to
affect one in three adults in the United States.[1] Its prevalence in children is also increasing in
parallel with childhood obesity.[2–4] The severity of NAFLD is varied and could range from
simple hepatic steatosis or non-alcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis
(NASH), a progressive condition that could lead to cirrhosis, hepatocellular cancer or liver fail-
ure.[5] Since NASH is a histologic diagnosis, a definitive diagnosis requires the patient to
undergo a liver biopsy.[5] Currently, the therapeutic end point in clinical trials for NASH
requires a liver biopsy at enrollment and after completion of the study in order to show resolu-
tion of NASH with therapeutic intervention.[6] A non-invasive biomarker for the diagnosis
and severity of NAFLD that can also change dynamically with histological improvement in a
treatment trial is very desirable and currently an unmet need.
In addition to metabolic factors, sterile inflammation caused by free fatty acids (FFA), che-
mokines, cytokines, or adipokines in NASH results in the release of endogenous molecules
termed damage-associated molecular patterns (DAMPs).[7–9] Serum high mobility group
box 1 protein (HMGB1), an evolutionarily conserved protein is a DAMP that serves to acti-
vate innate immunity and also act as a ligand for Toll-like receptors.[10] Although, HMGB1
was initially described as a late mediator of sepsis due to its releases from necrosis of cells, its
role in sterile inflammation was subsequently recognized.[11] Therefore, it may also serve as
an early mediator in the context of sterile inflammation that occurs in NASH.[7,12,13] Par-
ticularly, the switch of hepatic stellate cells toward a proinflammatory and profibrogenic phe-
notype through increased expression of chemokines such as monocyte chemoattractant
protein-1 (MCP-1) and transforming growth factor beta 1(TGF-β) in NASH may be medi-
ated through HMGB1.[14,15] There is some suggestion that HMGB1 may also regulate cellu-
lar process such as autophagy and apoptosis, two predominant mechanisms implicated in the
pathophysiology of NASH.[16,17] Animal experiments reported HMGB1 release from hepa-
tocytes in response to FFA infusion and subsequent treatment with neutralizing antibody to
HMGB1 protected against FFA-induced tumor necrosis factor alpha and interleukin-6 pro-
duction.[18]
Levels of circulating HMGB1 are elevated in patients with acute liver failure and acetamino-
phen-induced acute liver injury and indicative of the severity of liver injury.[19–21] The corre-
lation between serum HMGB1 and histological severity of NAFLD as measured by NAFLD
activity score (NAS) failed to show a consistent relationship in adult patients.[22] Unfortu-
nately, the relationship between serum HMGB1 and fibrosis was not reported in this study.
[22] The biomarker potential for serum HMGB1 levels in NAFLD was recently investigated in
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a large cohort of children with varying degrees of fibrosis in children with biopsy-proven
NAFLD.[23] Plasma HMGB1 levels were higher in children with NAFLD than obese controls
and correlated with the degree of fibrosis.[23] The levels were markedly elevated in those with
clinically significant fibrosis (F2 stage of fibrosis) when compared to those without.[23]
There was also a strong association with other biomarkers of fibrosis such as keratin 18 frag-
ment levels and hyaluronic acid indicative of HMGB1-fibrosis relationship.[23] Although,
there was no correlation with degree of hepatic inflammation, the correlation between levels of
plasma HMGB1 levels and TGF-β and MCP-1 is suggestive of the critical role of HMGB1 in
the pathogenesis of NAFLD.[23] Currently, there are no studies that examined the biomarker
potential of HMGB1 in adult patients with NAFLD. Furthermore, it is not known if HMBG1
levels improve with treatment interventions and serve as a biomarker of treatment response.
Testing the reliability and reproducibility of serum HMGB1 level as a biomarker for NAFLD
severity is therefore very critical. In the current study, we investigated the relationship between
NAFLD phenotype and treatment response on levels of serum HMGB1 in adults and children
participating in PIVENS and TONIC clinical trials.
Materials and methods
Biosamples archived (stored -70˚C) from PIVENS and TONIC clinical trials were obtained
through an ancillary study proposal submitted to the NASH Clinical Research Network
(NASH CRN). The current study was reviewed by Indiana University Institutional Review
Board (IRB). It was determined that IU IRB Review was not required (1604580147) since the
authors did not have access to identifying information of the sample donors either as the phy-
sicians of the donors or upon access to the samples. Study design, demographic details, and
clinical trial endpoints in these two trials have been previously published.[24,25] Briefly, in the
PIVENS trial, the efficacy of daily pioglitazone (30mg) or vitamin E (800 IU), vs. placebo was
assessed in 247 non-diabetic, adult patients with histologically defined NASH with a primary
endpoint of overall improvement in liver histology at week 96 compared to baseline.[26] In
the TONIC trial, the efficacy of vitamin E (800 IU/day), metformin (1000 mg/day) or placebo
in 173 children with biopsy-proven NAFLD with sustained reduction in serum alanine amino-
transferase (ALT) levels as the primary endpoint.[24] The overall improvement in liver histol-
ogy at week 96 as compared to baseline was also assessed.[24] The clinical trials were approved
by the review board at each participating center, and all subjects gave written informed con-
sent.[27,28] Informed consent provided by the participants allowed for ancillary studies to be
conducted on archived biological samples at a later point. We have included selected baseline
characteristics for the PIVENS and TONIC patients with a serum HMGB1 measured at either
baseline or 96 weeks who comprised the study population (S1 Table). Baseline and 96-week
liver histology from both the studies was centrally scored by NASH CRN Pathology Commit-
tee (10 hepatopathologists blinded to clinical and treatment data) according to the previously
published NASH CRN histological scoring system.[29] Briefly, the following histologic data
were analyzed and diagnosis rendered by the Pathology Committee (i.e. “not steatohepatitis”,
“borderline, zone 3 pattern”, “definite steatohepatitis”); the aggregate NAFLD activity score
(NAS); the score of each component of the NAS (steatosis (0–3), lobular inflammation (0–3),
ballooning (0–2)), and fibrosis scores (0,1a,1b,1c,2,3).[30] The serum HMGB1 concentration
was measured by ELISA following the manufacturer’s protocol (IBL International, Hamburg,
Germany). The absorbance was determined at 450nm with the Vmax Kinetic Microplate
reader by Molecular Devices M2 (Sunnyvale, CA). The standard curve and HMGB1 values
were determined using the Soft-max Pro software (version 6.2) accompanying the microplate
reader.
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Statistical analysis
In separate analyses for adults with NASH (PIVENS trial) and children with NAFLD (TONIC
trial), serum HMGB1 levels were compared with histologic features, and P values were derived
from linear regression of the rank of the serum HMGB1 values on various histological features.
Multiple linear regression models adjusting for the baseline HMGB1 value were used to assess
differences between mean changes of HMGB1 levels at 96 weeks from baseline between
different comparator groups. P values for the differences in the serum HMGB1 time trends by
treatment group or histological improvement were derived from separate multiple linear
regression models for serum HMGB1 change in relation to independent variables as follows:
baseline serum HMGB1 level, indicator variables for the classification group of interest,
spline-type indicator variables for each time period, and interaction terms to allow the between
group differences to vary with time; these regression models also included the use of general-
ized estimating equations (GEE) with robust variance estimation to account for within-patient
correlations in repeated HMGB1 measures. All P values were 2-sided and nominal, and a P
value <0.05 was considered statistically significant. The Stata 12 software (version 12.1, Stat-
Corp, Cary, NC) and SAS version 9.3 (SAS Institute Inc., College Station, TX) were used for
the statistical analyses.
Results
Study population
Out of 243 adult patients with NASH, who participated in the PIVENS trial, 125 serum sam-
ples from baseline, and 207 samples from week 96 were available for the current study. The
median (IQR) duration between liver biopsy and sample used for measuring serum HMGB1
was 49 (23, 95) days at baseline, whereas it was only 2 (1, 9) days at the 96-week visit. Out of
173 children and adolescents who participated in the TONIC trial, 164 serum samples from
baseline, and 109 samples from week 96 were available for the current study. The median
(IQR) duration between liver biopsy and sample for serum HMGB1 measurement was 29 (14,
58) days at baseline and was only 2 (1, 2) days at the 96-week visit. The Spearman’s rank coeffi-
cient (rho) showed no correlation between adult or pediatric HOMA-IR (insulin resistance)
and HMGB1, or BMI for adults, or leptin for children.
Cross-sectional relationship between serum HMGB1 levels and
histological severity of NAFLD
Due to the proximity of the liver biopsy and serum HMGB1 measurements, our cross-sectional
analyses were undertaken on HMGB1 measurements and liver histology from the 96-week
visit. There were no significant relationships between serum HMGB1 levels and a histological
diagnosis of steatohepatitis, stage of fibrosis, grade of steatosis or severity of lobular inflamma-
tion, hepatocyte ballooning, and portal inflammation among the 207 adults who underwent
liver biopsy at the conclusion of the PIVENS trial (Table 1). Similarly, serum HMGB1 levels
were not associated with a histological diagnosis of steatohepatitis, fibrosis stage, steatosis grade
or severity of lobular inflammation, hepatocyte ballooning and portal inflammation among
109 children who underwent liver biopsy at the conclusion of the TONIC trial (Table 1).
Relationship between different treatments and changes in serum
HMGB1 levels
In the subset of 105 patients in the PIVENS trial and 109 patients in the TONIC trial with
paired samples from baseline and 96 weeks, the effect of different treatments on serum
Serum HMGB1 and changes in liver histology in NAFLD
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HMGB1 levels was examined. In the PIVENS trial, serum HMGB1 levels did not change sig-
nificantly during treatment with placebo, vitamin E therapy (P = 0.81) or pioglitazone
(P = 0.09) (Fig 1, top panel). Serum HMGB1 levels did not differ between (a) histological
improvement vs. no improvement (P = 0.85, Fig 1, middle panel) and (b) resolution of NASH
vs. no resolution (P = 0.29, Fig 1, bottom panel). At 96 weeks, serum HMGB1 levels did not
differ among individuals in three different treatment arms (Vitamin E vs. Placebo: P = 0.83
and Pioglitazone vs. Placebo: P = 0.84) (Table 2).
In the TONIC trial, serum HMGB1 levels did not change significantly during treatment
with placebo, metformin (P = 0.15) or vitamin E (P = 0.23) therapy (Fig 2, top panel). Serum
HMGB1 levels decreased with both metformin and vitamin E at week 96, but once again the
decrease was not significantly different when compared to the placebo arm (Table 2). Serum
HMGB1 levels did not differ among individuals with or without treatment response (per pro-
tocol) during the clinical trial (P = 0.29), irrespective of treatment assignment (Fig 2, middle
panel). Similarly, serum HMGB1 levels did not differ among individuals with or without reso-
lution of NASH (P = 0.19) irrespective of treatment assignment (Fig 2, bottom panel).
Table 1. Cross-sectional relationship between serum HMGB1 and various histological features in adults and children with NAFLD.
Histological feature PIVENS (N = 207) P* TONIC (N = 109) P*
No Mean ± SD (ng/mL) No. Mean ± SD (ng/mL)
Fibrosis stage: 0.48 0.31
None 69 1.2 ± 1.8 38 1.4 ± 2.1
Mild 65 2.0 ± 2.8 35 2.0 ± 3.6
Moderate 37 1.5 ± 1.9 17 0.8 ± 1.7
Bridging 27 1.9 ± 2.5 17 0.9 ± 1.3
Cirrhosis 9 2.1 ± 2.6 0 --
Steatosis grade: 0.97 0.28
 33% 12 1.7 ± 2.4 50 1.1 ± 1.7
34–66% 52 1.6 ± 2.1 26 1.5 ± 2.3
> 66% 26 1.4 ± 2.1 31 1.9 ± 3.7
Lobular inflammation: 0.94 0.29
< 2 foci 16 1.6 ± 2.3 70 1.5 ± 2.9
 2 foci 45 1.8 ± 2.4 37 1.3 ± 1.8
Hepatocellular ballooning: 0.94 0.40
None 93 1.7 ± 2.6 61 1.6 ± 2.9
Few 47 1.3 ± 2.0 29 1.8 ± 2.4
Many 65 1.7 ± 2.1 17 0.6 ± 1.0
Portal inflammation: 0.49 0.74
None 28 1.6 ± 2.3 17 1.0 ± 1.7
Few 14 1.6 ± 2.3 76 1.5 ± 2.8
Many 37 1.9 ± 2.3 14 1.4 ± 2.2
Steatohepatitis diagnosis: 0.87 0.87
None 73 1.7 ± 2.6 46 1.1 ± 1.7
Borderline suspicious zone 3 45 1.5 ± 2.3 20 1.9 ± 2.4
Borderline, suspicious zone 1 0 -- 10 3.5 ± 5.9
Definite 87 1.7 ± 2.1 31 1.0 ± 1.6
* HMGB1 levels assayed from the PIVENS and TONIC participants’ serum collected at 96 weeks.
P values (2-sided) for the association of histological feature and HMGB1 were derived from linear regression of the rank of the HMGB1 value on the
histological feature.
https://doi.org/10.1371/journal.pone.0185813.t001
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Fig 1. Serum HMGB1 levels during the PIVENS trial in the three treatment groups. At baseline, serum
HMGB1 levels among the three treatment groups were similar. Top panel: Serum HMGB1 levels did not
change significantly during treatment either with placebo, vitamin E therapy (P = 0.81) or pioglitazone
(P = 0.09). Middle panel: Serum HMGB1 levels did not differ among individuals with or without histological
improvement irrespective of treatment assignment during study duration (P = 0.85). Bottom panel: Similarly,
serum HMGB1 levels did not differ among individuals with or without resolution of NASH irrespective of
treatment assignment during study duration (P = 0.29).
https://doi.org/10.1371/journal.pone.0185813.g001
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Relationship between changes in serum HMGB1 levels and histological
response irrespective of treatment assignment
In the PIVENS trial, serum HMGB1 levels were not significantly different between patients
with and without histologic response (P = 0.90) or with or without resolution of NASH
(P = 0.30) (Fig 1 middle panel and bottom panel). The mean change in the serum HMGB1 lev-
els at week 96 irrespective of treament assignment was not statistically significantly different
(-0.5 ± 1.5 vs. -0.5 ± 2.5 ng/mL, P = 0.22) (S2 Table) between the patients who did and did not
achieve histological improvement and with or without resolution of NASH (No NASH resolu-
tion vs. NASH resolution: -0.6 ± 2.5 vs. -0.1 ± 2.2 ng/mL, P = 0.57) (S3 Table). In the TONIC
trial, serum HMGB1 levels between patients during the trial were not significantly different for
overall histologic response (P = 0.30) (Fig 2 and S4 Table) or resolution of NASH (P = 0.20)
(Fig 2 and S5 Table). The mean change in serum HMGB1 levels after 96 weeks of therapy was
-0.4 ± 2.4 ng/mL in those with histologic improvement compared to 0.6 ± 2.1 ng/mL in those
without (P = 0.32) (S4 Table). The mean change in serum HMGB1 levels after 96 weeks of
therapy was -0.4 ± 2.6 ng/mL in those with NASH resolution compared to 0.7 ± 1.8 ng/mL in
those without (P = 0.15) (S5 Table).
Relationship between serum HMGB1 levels and serum ALT levels
In the PIVENS trial, there was no relationship between serum ALT and HMGB1 levels
[change in serum ALT for every 10 ng/mL decrease in HMGB1 was -0.1 (-0.4, 0.1),
P = 0.33]. In the TONIC trial as well, there was no relationship between serum ALT and
HMGB1 levels [change in serum ALT for every 10 ng/mL decrease in HMGB1 was -0.3
(-0.8, 0.2), P = 0.24].
Discussion
Studies that examined the relationship between serum HMGB1 and fibrotic disorders such as
idiopathic pulmonary fibrosis and systemic sclerosis have yielded contrasting results.[31,32]
Studies that examined the relationship between serum and tissue levels of HMGB1 have also
failed to show any consistent relationship.[31,32]
Sterile inflammation and subsequent release of DAMPs from hepatocyte injury are key pro-
cesses in the pathophysiology of NASH. The significant association between increased levels of
plasma HMGB1 and a higher degree of liver fibrosis in the recent pediatric study highlighted
its biomarker potential for non-invasive diagnosis of NASH.[23] However, in the current
study, we failed to show any significant relationship between serum HMGB1 levels and degree
of liver fibrosis or histologic severity in either children or adults with biopsy-proven NAFLD.
Table 2. Change in serum HMGB1 in paired samples (baseline and 96 weeks) in PIVENS and TONIC participants by Treatment Group.
Clinical trial Mean (± SD) change in HMGB1 from baseline to 96 weeks (ng/mL) P*
Treatment group
PIVENS Placebo (n = 42) Pioglitazone (n = 42) Vitamin E (n = 41) Vitamin E vs. Placebo Pioglitazone vs. Placebo
-0.5 ± 2.6 -0.2 ± 2.1 -0.5 ± 2.2 0.83 0.84
TONIC Placebo (n = 32) Metformin (n = 40) Vitamin E (n = 37) Vitamin E vs. Placebo Metformin vs. Placebo
-0.1 ± 1.9 -0.2 ± 2.1 -0.7 ± 3.4 0.29 0.91
* For the mean change in scores, P values were calculated with multiple linear regression models with two indicator variables for the effect of treatment
versus placebo, adjusting for the baseline value of the outcome.
https://doi.org/10.1371/journal.pone.0185813.t002
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Fig 2. Serum HMGB1 levels during the TONIC trial in the three treatment groups. At baseline, serum
HMGB1 levels among the three treatment groups were similar. Top panel: serum HMGB1 levels did not
change significantly during treatment either with placebo, metformin (P = 0.15) or vitamin E (P = 0.23) therapy.
Middle panel: Serum HMGB1 levels did not differ among individuals with or without treatment response (per
protocol) during study duration (P = 0.29), irrespective of treatment assignment. Bottom panel: Similarly,
serum HMGB1 levels did not differ among individuals during study duration with or without resolution of NASH
(P = 0.19) irrespective of treatment assignment.
https://doi.org/10.1371/journal.pone.0185813.g002
Serum HMGB1 and changes in liver histology in NAFLD
PLOS ONE | https://doi.org/10.1371/journal.pone.0185813 November 2, 2017 8 / 13
Moreover, changes in serum HMGB1 levels did not differ significantly with vitamin E, metfor-
min or pioglitazone therapy when compared to placebo. Irrespective of treatment assignment,
changes in serum HMGB1 levels did not differ in those with or without a treatment response
or resolution of NASH. The biomarker potential of serum HMGB1 for the diagnosis of
NAFLD in children could not be evaluated in the current study as the study design of TONIC
precluded enrollment of children without NAFLD.
Lack of relationship between serum HMGB1 and degree of fibrosis in the current
study is in contrast to previously published study despite similar sample size, range of val-
ues, and assay used for measurement serum HMGB1 levels. Although perplexing, the
discrepancy may be related to differences in the NAFLD phenotype; the current study
included 32% advanced fibrosis vs. 18% in the Italian study.[23] The lack of association in
the with both adults and children although disappointing, highlights the challenges in
understanding the relationship between serum levels of DAMPs and understand their role
in NASH pathogenesis.[33] Moreover, circulating HMGB1 and liver HMGB1 could repre-
sent two different pools and further studies that simultaneously quantify the hepatic and
peripheral HMGB1to examine the relationship between DAMPs and NASH pathogenesis
are awaited.
Single blood biomarker to predict the presence or severity of NAFLD is inherently challeng-
ing due to its complex pathophysiology. Caution should be exercised when using a single bio-
marker to predict disease severity. To better comprehend the findings from the present study,
factors that could alter HMGB1 function and levels would merit further discussion. The cellu-
lar source for HMGB1 is the nucleus and its acetylation in the cytoplasm stops its reentry into
the nucleus with subsequent migration into cytoplasmic secretory vesicles.[34] HMGB1 is also
sensitive to the redox state and is rapidly inactivated in the normal oxidative extracellular envi-
ronment.[35] In general, it is well accepted that innate immune cells secrete the acetylated
form (active secretion), and necrotic dying cells release non acetylated form.[36] Future stud-
ies should consider measuring the acetylated form and examine if these levels are down-regu-
lated with NASH resolution. Also, studies have also shown that short-term fasting causes a
reduction in circulating HMGB1 due to cytoplasmic HMGB1 translocation and induction of
autophagy.[17] In the current study, the mean serum levels of HMGB1 appear to be lower
than the previously reported values in literature despite similar methodology to our previously
published work. [23,37]
In summary, serum HMGB1 levels did not correlate with NAFLD severity or improve-
ments in liver histology or serum ALT. We speculate that one or a combination of factors
could perhaps explain the lack the relationship between serum HMGB1 and NAFLD severity.
Future studies could perhaps either measure acetylated HGMB1, HMGB1 isoforms or measure
in a non-fasting state with a standardized meal.
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